ALX ONCOLOGY HOLDINGS INC — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 78/100
What the filing says
ALX Oncology entered a Loan and Security Agreement with HSBC Ventures USA dated June 25, 2026, for up to $50M in term loan advances ($30M Term A, $10M Term B, $10M Term C) to repay existing Oxford-SVB obligations. Draw periods are conditional on clinical milestones (ASPEN-09 Phase 2 data, ALX2004 Phase 1 safety data). Interest accrues at the greater of Prime Rate or 6.0%, with 2% prepayment premium in year 1, 1% in year 2, zero thereafter. Maturity June 1, 2030; 24-month amortization starting July 2028 (reduced to 12 months if milestone achieved). Security interest granted over all assets; guarantees from Parent (ALX Oncology Holdings) and Irish subsidiary.
Why this rating
Material refinancing relative to $18M company: $50M facility is 2.8x market cap, replaces prior debt, milestone-gating provides financial flexibility but success-dependent. Significant but not transformational; standard biotech debt structure with clinical conditions.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.